Opnurasib (JDQ443) is an oral small molecule that selectively targets the KRAS G12C mutant protein and inhibits its signaling, which drives tumor cell growth and proliferation. It is studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.